Daniil Gataulin
Stock Analyst at Chardan Capital
(3.52)
# 1,491
Out of 4,479 analysts
33
Total ratings
31.03%
Success rate
12.36%
Average return
Main Sectors:
Top Industries:
9 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| EYPT EyePoint Pharmaceuticals | Maintains: Buy | $28 | $8.01 | +249.56% | 6 | Jun 28, 2024 | |
| OCS Oculis Holding AG | Reiterates: Buy | $30 | $11.87 | +152.74% | 3 | Jun 11, 2024 | |
| CGTX Cognition Therapeutics | Initiates: Buy | $11 | $1.82 | +504.40% | 1 | Jun 6, 2024 | |
| OCGN Ocugen | Maintains: Buy | $5 | $1.61 | +210.56% | 5 | May 15, 2024 | |
| ADVM Adverum Biotechnologies | Reiterates: Buy | $40 | $6.84 | +484.80% | 4 | Mar 19, 2024 | |
| PPBT Purple Biotech | Maintains: Buy | $11 | $0.37 | +2,875.39% | 1 | Mar 7, 2024 | |
| RGNX REGENXBIO | Maintains: Buy | $52 | $10.75 | +383.72% | 6 | Mar 7, 2024 | |
| OTLK Outlook Therapeutics | Upgrades: Buy | $60 | $7.09 | +746.26% | 5 | Feb 15, 2024 | |
| KOD Kodiak Sciences | Downgrades: Neutral | n/a | $2.24 | - | 2 | Jul 25, 2023 |
EyePoint Pharmaceuticals
Jun 28, 2024
Maintains: Buy
Price Target: $28
Current: $8.01
Upside: +249.56%
Oculis Holding AG
Jun 11, 2024
Reiterates: Buy
Price Target: $30
Current: $11.87
Upside: +152.74%
Cognition Therapeutics
Jun 6, 2024
Initiates: Buy
Price Target: $11
Current: $1.82
Upside: +504.40%
Ocugen
May 15, 2024
Maintains: Buy
Price Target: $5
Current: $1.61
Upside: +210.56%
Adverum Biotechnologies
Mar 19, 2024
Reiterates: Buy
Price Target: $40
Current: $6.84
Upside: +484.80%
Purple Biotech
Mar 7, 2024
Maintains: Buy
Price Target: $11
Current: $0.37
Upside: +2,875.39%
REGENXBIO
Mar 7, 2024
Maintains: Buy
Price Target: $52
Current: $10.75
Upside: +383.72%
Outlook Therapeutics
Feb 15, 2024
Upgrades: Buy
Price Target: $60
Current: $7.09
Upside: +746.26%
Kodiak Sciences
Jul 25, 2023
Downgrades: Neutral
Price Target: n/a
Current: $2.24
Upside: -